NEW YORK (GenomeWeb) — Interpace Diagnostics this week reported a surge in revenues for 2015, reflecting the impact of the acquisition of molecular diagnostic assets during the last two quarters of the previous year.

For the 12-month period ended Dec. 31, Interpace's revenues jumped more than 525 percent to $9.4 million from $1.5 million.

It posted a net loss of $11.4 million, or $.73 per share, versus a net loss of $16.1 million, or $1.08 per share, for FY2014. Its loss from continuing operations climbed to $31 million from $13.5 million year over year. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.